FOLD broke above its upper Bollinger Band on September 11, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In of the 39 cases the stock fell afterwards. This puts the odds of success at .
The Momentum Indicator moved below the 0 level on September 20, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on FOLD as a result. In of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for FOLD turned negative on September 20, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .
FOLD moved below its 50-day moving average on September 18, 2023 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FOLD crossed bearishly below the 50-day moving average on August 23, 2023. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FOLD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where FOLD advanced for three days, in of 301 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FOLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (31.546) is normal, around the industry mean (22.620). P/E Ratio (0.000) is within average values for comparable stocks, (131.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.087). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (10.173) is also within normal values, averaging (306.625).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FOLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of orally active drugs to treat human genetic diseases
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
SMN | 10.02 | 0.28 | +2.86% |
ProShares UltraShort Materials | |||
FDEV | 24.75 | -0.19 | -0.76% |
Fidelity® International Multifactor ETF | |||
SIXH | 31.79 | -0.45 | -1.39% |
ETC 6 Meridian Hdg Eq-Idx Opt Strat ETF | |||
ILCG | 59.11 | -0.94 | -1.56% |
iShares Morningstar Growth ETF | |||
SWZ | 7.56 | -0.18 | -2.33% |
Swiss Helvetia Fund |
A.I.dvisor indicates that over the last year, FOLD has been loosely correlated with MNKD. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if FOLD jumps, then MNKD could also see price increases.
Ticker / NAME | Correlation To FOLD | 1D Price Change % | ||
---|---|---|---|---|
FOLD | 100% | +2.34% | ||
MNKD - FOLD | 51% Loosely correlated | +0.50% | ||
EDIT - FOLD | 49% Loosely correlated | -0.70% | ||
BEAM - FOLD | 48% Loosely correlated | +2.56% | ||
RVMD - FOLD | 48% Loosely correlated | -1.90% | ||
RGNX - FOLD | 47% Loosely correlated | +1.72% | ||
More |
Ticker / NAME | Correlation To FOLD | 1D Price Change % |
---|---|---|
FOLD | 100% | +2.34% |
drugs (undefined stocks) | 49% Loosely correlated | +0.50% |
oral products (undefined stocks) | 48% Loosely correlated | +1.63% |
biotechnology (undefined stocks) | 45% Loosely correlated | +0.37% |
diseases (undefined stocks) | 38% Loosely correlated | +0.09% |